Scarica l'app Stockscreener
14.19
2.47%
-0.36
Precedente Chiudi:
$14.55
Aprire:
$14.5
Volume 24 ore:
154.23K
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.84B
Reddito:
$65.48M
Utile/perdita netta:
$-94.46M
Rapporto P/E:
-19.24
EPS:
-0.7375
Flusso di cassa netto:
$-71.18M
1 W Prestazione:
-7.32%
1M Prestazione:
+4.88%
6M Prestazione:
-17.74%
1 anno Prestazione:
-7.01%
Intervallo 1D:
$14.04
$14.53
Intervallo di 1 settimana:
$14.04
$15.08
Portata 52W:
$12.66
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Nome
Mesoblast Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare MESO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
14.19 | 1.89B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-12-23 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-24 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-23 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Downgrade | Maxim Group | Buy → Hold |
| 2023-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | Iniziato | William Blair | Outperform |
| 2022-12-06 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-06 | Iniziato | Piper Sandler | Overweight |
| 2021-04-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-12-22 | Downgrade | Maxim Group | Buy → Hold |
| 2020-12-04 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2020-05-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-31 | Ripresa | H.C. Wainwright | Buy |
| 2018-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-08-31 | Iniziato | Oppenheimer | Outperform |
| 2017-06-08 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Mesoblast Ltd Adr Borsa (MESO) Ultime notizie
Mesoblast Limited (ASX:MSB) Heats Up Again as Biotech Investors Watch Its Next Move - Kalkine
Mesoblast (ASX: MSB) Slips as Investors Monitor Ryoncil Growth and Product Pipeline - Kalkine
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally - Kalkine
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
Daily Brief Australia: Genesis Minerals, Perpetual Ltd, Mesoblast Ltd, BHP Group Ltd, Pacific Niugini, D3 Energy, Noble Helium and more - Smartkarma
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Why Is Mesoblast Stock Up Today? - Kalkine
Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range? - Kalkine
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewswire Inc.
Mesoblast (ASX:MSB) Shares Rise: A Closer Look at the Cell Therapy Company's Market Position - Kalkine
symbol__ Stock Quote Price and Forecast - CNN
Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections - Sharecafe
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen - Barchart.com
Mesoblast (ASX:MSB): The Stem Cell Therapy Company on the Cusp of Commercial Reality - Kalkine
Mesoblast (ASX:MSB) Climbs as Biotech Bulls Return to the ASX Healthcare Trade - Kalkine
LWB1 Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LSX:A4004R) - TradingView
A4004R Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LS:A4004R) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (NASDAQ:MESO) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (GETTEX:LWB1) - TradingView
Mesoblast Ltd consensus and trial focus, shares watched on Nasdaq - Ad-hoc-news.de
ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
MESO - Finviz
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Mesoblast LimitedDepositary Receipt (MESO) price target decreased by 14.96% to 15.33 - msn.com
Mesoblast completes enrollment in back pain therapy trial - Investing.com
Mesoblast acquires CAR technology license from Mayo Clinic - Investing.com
FDA clears Mesoblast DMD trial for Ryoncil in children - Investing.com
Mesoblast drops after Ryoncil sales data for March quarter - Seeking Alpha
MESO Ignites 10% Surge: A Biotech Spark Ignited Without a Visible Fuse - Bitget
Philip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
Mesoblast issues 5 million unquoted warrants as fee for US$50 million convertible note facility - MSN
Mesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
Gregory George beneficial owner at Mesoblast (OTC: MEOBF) with 22.36% stake - Stock Titan
MEOBF SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
Earnings call transcript: Mesoblast’s strong Q1 2026 performance boosts outlook - Investing.com
FARM 51 GROUP S.A.ZY -,1.XFRA: MWBMUHANDELSUNTERBRECHUNGTEIL 5 - aktiencheck.de
Mesoblast (NASDAQ: MESO) holders may resell 500,000 ADSs via warrants - Stock Titan
Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum - Stocks Down Under
Mesoblast announces board leadership changes as company evolves - Investing.com South Africa
Mesoblast Issues 5 Million Unquoted Warrants as Fee for US$50 Million Convertible Note Facility - TipRanks
Mesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales - Investing.com
Insights: Mesoblast Ltd (ASX:MSB) - smallcaps.com.au
Mesoblast rides early ryoncil® momentum, tightens cash discipline, and prepares for next growth phase - Proactive financial news
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Mesoblast Ltd Adr Azioni (MESO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mesoblast Ltd Adr Azioni (MESO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| George Gregory | Director |
Apr 10 '26 |
Buy |
1.48 |
2,324,072 |
3,439,627 |
8,324,072 |
| George Gregory | Director |
Apr 09 '26 |
Buy |
1.44 |
1,586,890 |
2,277,350 |
13,586,890 |
| George Gregory | Director |
Apr 09 '26 |
Buy |
8.59 |
1,981,890 |
17,015,467 |
13,586,890 |
| George Gregory | Director |
Apr 04 '26 |
Buy |
1.42 |
4,000,000 |
5,680,000 |
12,000,000 |
| George Gregory | Director |
Apr 10 '26 |
Buy |
1.48 |
2,324,072 |
3,439,627 |
8,324,072 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):